From Name

From Email

To Name

To Email

Message

Pembrolizumab/chemo significantly improves PFS in frontline PD-L1-high TNBC

from OncLive

Pembrolizumab/chemo significantly improves PFS in frontline PD-L1-high TNBC OncLive Pembrolizumab (Keytruda) in combination with several chemotherapy partners led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as a first-line treatment for patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1, according to results of the phase 3 KEYNOTE-355 trial that were presented during the 2020 ASCO Virtual Scientific Program. READ MORE

more